Emcure Pharmaceuticals Limited
EMCURE · General/Diversified · NSE
₹1,608
Current Market Price
Fair Value (DCF)
₹937
Margin of Safety
-41.7%
Updated 1d ago
YieldIQ Score
50/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
64%
ROE
14.7%
Debt/Equity
0.00
WACC
12.8%
Market Cap
₹0.30 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.0%
Return on capital employed
EV / EBITDA
19.2×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
7.9×
EBIT covers interest
Current Ratio
1.71×
Short-term liquidity
Asset Turnover
0.93×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,607.7
Bear case
₹571.06
MoS -181.5%
Base case
₹936.6
MoS -71.7%
Bull case
₹1,173.5
MoS -37.0%
Ratio Trends
EMCURE · last 4 annual periods
ROE
14.7%
ROCE
26.4%
Operating Margin
—
Debt / Equity
0.22×
PE
—
EV / EBITDA
—
Historical Financials
EMCURE · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹5766 Cr | ₹5931 Cr | ₹6582 Cr | ₹7808 Cr | +10.6% |
| EBITDA | ₹1350 Cr | ₹1170 Cr | ₹1240 Cr | ₹1495 Cr | +3.5% |
| EBIT | — | — | — | — | — |
| PAT | ₹662 Cr | ₹532 Cr | ₹498 Cr | ₹681 Cr | +1.0% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹768 Cr | ₹747 Cr | ₹1097 Cr | ₹852 Cr | +3.5% |
| CapEx | ₹-397 Cr | ₹-403 Cr | ₹-307 Cr | ₹-407 Cr | — |
| FCF | ₹371 Cr | ₹343 Cr | ₹790 Cr | ₹445 Cr | +6.2% |
| Total Assets | ₹6063 Cr | ₹6673 Cr | ₹7806 Cr | ₹8233 Cr | +10.7% |
| Total Debt | ₹2217 Cr | ₹2334 Cr | ₹2335 Cr | ₹1023 Cr | -22.7% |
| Shareholders' Equity | ₹2114 Cr | ₹2650 Cr | ₹3122 Cr | ₹4642 Cr | +30.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
EMCURE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| JBCHEPHARM JBCHEPHARM | — | — | Pending | 19.2% | — |
| GLAND Gland Pharma Limited | -12.7% | 64 | Near Fair Value | 7.6% | — |
| AJANTPHARM Ajanta Pharma Limited | -32.4% | 58 | Above Fair Value | 24.3% | — |
| IPCALAB IPCALAB | — | — | Pending | 8.8% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹3.00/sh
Last payout
2025-08-14
₹3.00
Peak payout
₹3.00
Trailing yield
0.19%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Emcure Pharmaceuticals Limited (EMCURE.NS) trades at 1607.70 vs a model fair value of 936.60, a gap of -41.7%. Piotroski F-score: 6/9. Mo...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of EMCURE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for EMCURE →
Compare
Head-to-head with peers
Compare EMCURE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse EMCURENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.